Home - Clinical Trials Arena
WEBPerimeter completes enrolment for AI-assisted breast imaging trial. The primary endpoint results from the trial are expected by the end of the year and will be used to support an FDA approval for the OCT B-Series device. More themes.
Gilead’s lenacapavir: HIV prospects strongest in long-acting …
WEBAug 25, 2021 · Gilead’s lenacapavir will find its strongest niche as a long-acting HIV combination treatment, experts said. Manasi Vaidya August 25, 2021. Gilead announced a collaboration with Merck in March to study lenacapavir with islatravir, a nucleoside reverse transcriptase translocation inhibitor (NRTTI), which is also a new drug class in HIV.
Valneva and Pfizer report Lyme disease vaccine trial data
WEBSep 3, 2024 · Valneva and Pfizer have reported positive data from the Phase II VLA15-221 clinical trial of a second booster dose of their Lyme disease vaccine candidate, VLA15, administered one year after the initial booster.. VLA15 is an investigational multivalent protein subunit vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacterium responsible for Lyme disease.
KERENDIA (finerenone) to Treat CKD Associated with Type 2 …
WEBSep 8, 2023 · KERENDIA (finerenone) is the first nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of chronic kidney disease (CKD) associated with type 2 diabetes (T2D). Credit: Bayer. CKD associated with type 2 diabetes is the leading cause of renal failure worldwide. Credit: Kateryna Kon / Shutterstock.
Nxera wins $35m after Phase II schizophrenia trial success
WEBSep 2, 2024 · Japanese biopharma Nxera Pharma has secured $35m in milestone payments from Neurocrine Biosciences following positive Phase II trial data of NBI-1117568 (NBI-568) in adults with schizophrenia. The two companies teamed up in November 2021 to develop novel muscarinic receptor antagonists. Nxera – which has a …
News - Clinical Trials Arena
WEBExscientia outline robot and AI use in drug discovery workflow. As AI continues to disrupt the healthcare industry, more pharma companies are using algorithms to design drug molecules. AI-driven pharma…. Jenna Philpott.
Obesity: Six trials to watch over the next 12 months
WEBAbigail Beaney June 30, 2023. Here are some trials for obesity medications to watch over the next 12 months. Image credit: Zdenek Macat / Getty Images. The approval of Novo Nordisk ’s Wegovy in 2021 catapulted the landscape of obesity medications as companies race to develop other drugs which can provide higher levels of efficacy. Free ...
BioNTech treats first subject in Phase II cancer vaccine trial
WEBOct 20, 2023 · BioNTech has treated the first subject in a Phase II clinical trial of cancer vaccine candidate, autogene cevumeran (BNT122, RO7198457) to treat resected pancreatic ductal adenocarcinoma (PDAC), a type of solid tumour. Autogene cevumeran is a messenger ribonucleic acid (mRNA)-based individualised neoantigen-specific immunotherapy (iNeST) candidate.
Arrowhead to file NDA after pivotal rare disease trial meets all …
WEBSep 3, 2024 · Arrowhead Pharmaceuticals is looking to file a new drug application (NDA) with the US Food and Drug Administration (FDA) after announcing full data from a pivotal trial of its lead candidate, plozasiran.. The Phase III Palisade study (NCT05089084) met its primary endpoint of fasting triglyceride level and all multiplicity-controlled key secondary endpoints, including statistically significant ...
Top Ongoing mRNA Herpes Vaccine Trials - Clinical Trials Arena
WEBFeb 2, 2023 · Pfizer and Moderna eye seasonal influenza. The two largest mRNA vaccine trials with readouts in 2023 are for seasonal influenza. First up, Moderna’s 6,102-patient, Phase III trial of mRNA-1010 (NCT05415462) has immunogenicity data expected in Q1 2023. The trial is testing mRNA-1010 against an …
- Some results have been removed